09:56 AM EST - BriaCell Therapeutics Corp. : Announced that the Company has signed a Master Service and Technology Agreement agreement with Prevail InfoWorks, Inc., a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork’s integrated real-time data analytics platform, The Single Interface ® , for clinical support and real-time data analysis. Prevail Partners, LLC (“Prevail Partners”), an investment fund and affiliate of InfoWorks, has agreed to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day volume-weighted average price of the common shares of the Company on the Nasdaq Stock Exchange. Subject to exchange approvals and other customary closing conditions, the subscription is expected to close on or about May 19, 2023. BriaCell Therapeutics Corp.
shares T.BCT are trading up 20 cents at $9.05.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BCT%3ACA&qmodStoryID=8016842024040020
